LY 3016859

Drug Profile

LY 3016859

Alternative Names: LY3016859; TGF-alpha/epiregulin monoclonal antibody

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors; Transforming growth factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic nephropathies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetic-nephropathies(In volunteers) in United Kingdom (SC)
  • 01 Aug 2015 Eli Lilly completes a phase I/II trial for Diabetic nephropathies in USA, United Kingdom & Bulgaria (NCT01774981)
  • 27 Mar 2013 Phase-I/II clinical trials in Diabetic nephropathies in Bulgaria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top